(Q38600697)

4 September 2017

title

Chimeric antigen receptor T-cell therapies for lymphoma (English)

1 reference

4 September 2017

Jennifer N Brudno

1

1 reference

4 September 2017

James N Kochenderfer

series ordinal

2

1 reference

4 September 2017

language of work or name

English

0 references

publication date

31 August 2017

1 reference

Nature Reviews Clinical Oncology

4 September 2017

published in

1 reference

Global cancer statistics, 2012

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

2016 US lymphoid malignancy statistics by World Health Organization subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Mantle cell lymphoma: evolving management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Relapsed Hodgkin lymphoma: management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Rituximab in Hodgkin lymphoma: is the target always a hit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

The basic principles of chimeric antigen receptor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Driving gene-engineered T cell immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CAR therapy: the CD19 paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Designing chimeric antigen receptors to effectively and safely target tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

The promise and potential pitfalls of chimeric antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

The pharmacology of second-generation chimeric antigen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Therapeutic T cell engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Adoptive cell transfer as personalized immunotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Relapse after allogeneic hematopoietic cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Graft-versus-leukemia effects of transplantation and donor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Graft-versus-host disease after donor leukocyte infusions: presentation and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Lessons learned from a highly-active CD22-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

CAR-T Cell Therapy for Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

High-density preculture of PBMCs restores defective sensitivity of circulating CD8 T cells to virus- and tumor-derived antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Toxicities of chimeric antigen receptor T cells: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Immune checkpoint blockade in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Towards understanding the peripheral T-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Reg

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Fully human CD19-specific chimeric antigen receptors for T-cell therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.128

7 January 2021

inferred from DOI database lookup

Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins

1 reference

12 December 2020

An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30

1 reference

12 December 2020

1 reference

12 December 2020

The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells

1 reference

12 December 2020

10.1038/NRCLINONC.2017.128

Identifiers

DOI

1 reference

4 September 2017

1 reference